EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting CD38 in Antibody-Mediated Rejection

Katharina A Mayer, Klemens Budde, Matthias Diebold, Philip F Halloran, Georg A Böhmig

Transplant International · 15.05.2025 · 38

DOI: 10.3389/ti.2025.14343 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant International, online erschienen am 15.05.2025. Verfasst von Katharina A Mayer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Graft Rejection, ADP-ribosyl Cyclase 1, Antibodies, Monoclonal, Isoantibodies. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-mediated rejection (AMR) remains a major challenge in clinical transplantation. Current therapies have yielded inconsistent outcomes, highlighting the need for innovative approaches. CD38, a multifunctional glycoprotein, is highly expressed on plasma cells and natural killer (NK) cells, potentially offering a dual mechanism of action that could intervene in the pathophysiologic course of AMR: depleting alloantibody-producing plasma cells and NK cells. This review focuses on recent results from CD38-targeted therapies, with felzartamab emerging as a promising option. Previous case reports and series suggested that off-label daratumumab treatment could effectively reverse AMR. Felzartamab has now demonstrated safety and efficacy in a phase 2 trial for late AMR. Reductions in microvascular inflammation, downregulation of rejection-associated transcripts, and decreases in donor-derived cell-free DNA paralleled a substantial decrease in NK cell counts. However, felzartamab did not significantly affect donor-specific antibodies, which may reflect its distinct mechanism of action, primarily involving antibody-dependent cellular cytotoxicity and phagocytosis. The effects on rejection activity may have a rapid onset, but are transient. The potential benefits of prolonged therapy are currently being investigated in a recently launched phase III trial. Future studies may expand the applications of CD38 targeting to early AMR or broader indications, such as DSA-negative microvascular inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft RejectionADP-ribosyl Cyclase 1Antibodies, MonoclonalIsoantibodiesHumansKiller Cells, NaturalAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell Cytotoxicity

Stichwörter der Autor:innen

CD38antibody-mediated rejectionkidney transplantationnatural killer cellstreatment

Substanzen

ADP-ribosyl Cyclase 1Antibodies, MonoclonaldaratumumabIsoantibodiesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Department of Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Alberta Transplant Applied Genomics Centre, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.

Zitieren

APA

Mayer, K. A., Budde, K., Diebold, M., Halloran, P. F., & Böhmig, G. A. (2025). Targeting CD38 in Antibody-Mediated Rejection. Transplant International, 38. https://doi.org/10.3389/ti.2025.14343

Vancouver

Mayer KA, Budde K, Diebold M, Halloran PF, Böhmig GA. Targeting CD38 in Antibody-Mediated Rejection. Transplant International. 2025;38. doi:10.3389/ti.2025.14343

BibTeX
@article{Mayer2025,
  author = {Mayer, Katharina A and Budde, Klemens and Diebold, Matthias and Halloran, Philip F and Böhmig, Georg A},
  title = {Targeting CD38 in Antibody-Mediated Rejection},
  journal = {Transplant International},
  year = {2025},
  volume = {38},
  doi = {10.3389/ti.2025.14343}
}
Kostenlos starten →